An ophthalmologist on this week's edition of In Touch on Radio 4 outlined that the CATT and IVAN studies showed similar outcomes from the two drugs, though with some concerns over the systemic load. What was interesting was that he suggested if NICE approved the cheaper drug he would have no hesitation using it. Apparently as long as there are court actions proceeding (Novartis is taking several south coast PCTs to court over the recommendation of the unlicensed drug) there are unlikely to be any changes in drug use and supply. The timing of the court actions now seems relevant and the UK legal system is more than likely to drag these out. Good work by the company!
Opinion